stocks logo

CRBU

Caribou Biosciences Inc
$
2.280
-0.09(-3.797%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.340
Open
2.200
VWAP
2.25
Vol
1.76M
Mkt Cap
212.05M
Low
2.1705
Amount
3.96M
EV/EBITDA(TTM)
--
Total Shares
90.32M
EV
3.59M
EV/OCF(TTM)
--
P/S(TTM)
20.96
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
1.80M
-13.58%
--
--
1.69M
-16.34%
--
--
1.64M
-52.56%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Caribou Biosciences, Inc. (CRBU) for FY2025, with the revenue forecasts being adjusted by 11.25% over the past three months. During the same period, the stock price has changed by 195.45%.
Revenue Estimates for FY2025
Revise Upward
up Image
+11.25%
In Past 3 Month
Stock Price
Go Up
up Image
+195.45%
In Past 3 Month
5 Analyst Rating
up Image
128.07% Upside
Wall Street analysts forecast CRBU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBU is 5.20 USD with a low forecast of 1.00 USD and a high forecast of 10.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
up Image
128.07% Upside
Current: 2.280
sliders
Low
1.00
Averages
5.20
High
10.00
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$9
2025-03-19
Reason
B of A Securities
Alec Stranahan
Strong Buy
Maintains
$13 → $11
2025-01-07
Reason
Citigroup
Yigal Nochomovitz
Strong Buy
Maintains
$30 → $6
2024-11-26
Reason
Citi lowered the firm's price target on Caribou Biosciences to $6 from $30 and keeps a Buy rating on the shares. The firm updated models in the Smid-cap biotech space following the Q3 reports. Citi adjusted its launch timelines for Caribou 's three cell therapies in development, saying its prior timelines were too aggressive.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$9
2024-11-15
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$9
2024-09-03
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$9
2024-08-14
Reason

Valuation Metrics

The current forward P/E ratio for Caribou Biosciences Inc (CRBU.O) is -1.72, compared to its 5-year average forward P/E of -4.35. For a more detailed relative valuation and DCF analysis to assess Caribou Biosciences Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.35
Current PE
-1.72
Overvalued PE
-0.16
Undervalued PE
-8.55

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.04
Current EV/EBITDA
-0.28
Overvalued EV/EBITDA
2.63
Undervalued EV/EBITDA
-6.71

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
32.57
Current PS
29.08
Overvalued PS
59.82
Undervalued PS
5.31

Financials

Annual
Quarterly
FY2025Q1
YoY :
-3.13%
2.35M
Total Revenue
FY2025Q1
YoY :
-6.71%
-42.91M
Operating Profit
FY2025Q1
YoY :
-3.01%
-39.99M
Net Income after Tax
FY2025Q1
YoY :
-6.52%
-0.43
EPS - Diluted
FY2025Q1
YoY :
-2.29%
-37.77M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+321.65%
-1.43K
FCF Margin - %
FY2025Q1
YoY :
+0.12%
-1.70K
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
14.4K
USD
3
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
20.4K
USD
Months
6-9
1
24.6K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1731.04% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.4M
Volume
1
6-9
Months
430.2K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
915.5K
Volume
Months
6-9
1
50.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

CRBU News & Events

Events Timeline

2025-04-24 (ET)
2025-04-24
16:24:38
Caribou reduces workforce by 32%, discontinues GALLOP and AMpLify trials
select
2025-03-10 (ET)
2025-03-10
16:19:43
Caribou Biosciences reports Q4 EPS (39c), consensus (42c)
select
2025-01-12 (ET)
2025-01-12
18:21:50
Caribou Biosciences initiates CB-010 GALLOP Phase 1 trial in lupus
select
Sign Up For More Events

News

7.0
07-25Globenewswire
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
9.0
06-20Benzinga
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
9.5
05-08SeekingAlpha
Caribou Bioscience GAAP EPS of -$0.43 beats by $0.01, revenue of $2.35M beats by $0.91M
Sign Up For More News

FAQ

arrow icon

What is Caribou Biosciences Inc (CRBU) stock price today?

The current price of CRBU is 2.28 USD — it has decreased -3.8 % in the last trading day.

arrow icon

What is Caribou Biosciences Inc (CRBU)'s business?

arrow icon

What is the price predicton of CRBU Stock?

arrow icon

What is Caribou Biosciences Inc (CRBU)'s revenue for the last quarter?

arrow icon

What is Caribou Biosciences Inc (CRBU)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Caribou Biosciences Inc (CRBU)'s fundamentals?

arrow icon

How many employees does Caribou Biosciences Inc (CRBU). have?

arrow icon

What is Caribou Biosciences Inc (CRBU) market cap?